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Inherited cavernous malformations of the central nervous
system: clinical and genetic features in 19 Swiss families
Abstract
Cavernous malformations (CCMs) are benign, well-circumscribed, and mulberry-like vascular
malformations that may be found in the central nervous system in up to 0.5% of the population.
Cavernous malformations can be sporadic or inherited. The common symptoms are epilepsy,
hemorrhages, focal neurological deficits, and headaches. However, CCMs are often asymptomatic. The
familiar form is associated with three gene loci, namely 7q21-q22 (CCM1), 7p13-p15 (CCM2), and
3q25.2-q27 (CCM3) and is inherited as an autosomal dominant trait with incomplete penetrance. The
CCM genes are identified as Krit 1 (CCM1), MGC4607 (CCM2), and PDCD10 (CCM3). Here, we
present the clinical and genetic features of CCMs in 19 Swiss families. Furthermore, surgical aspects in
such families are also discussed.
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Abstract  Cavernous malformations (CCMs) are benign, well-circumscribed, and mulberry-
like vascular malformations that may be found in the central nervous system in up to 0.5% of 
the population. Cavernous malformations can be sporadic or inherited. The common 
symptoms are epilepsy, hemorrhages, focal neurological deficits, and headaches. However, 
CCMs are often asymptomatic. The familiar form is associated with three gene loci, namely 
7q21-q22 (CCM1), 7p13-p15 (CCM2), and 3q25.2-q27 (CCM3) and is inherited as an 
autosomal dominant trait with incomplete penetrance. The CCM genes are identified as Krit 1 
(CCM1), MGC4607 (CCM2), and PDCD10 (CCM3). Here, we present the clinical and 
genetic features of CCMs in 19 Swiss families. Furthermore, surgical aspects in such families 
are also discussed.  
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Introduction 
Cavernous malformations (CCMs) of the central nervous system are well-circumscribed, 
lobulated, mulberry-like, and often encapsulated structures that can vary greatly in size [25]. 
They are found in about 0.5% of the population and represent approximately 10–20% of 
cerebral vascular lesions [22]. Microscopically, CCMs consist of enlarged thin-walled blood 
vessels without intervening neural tissue. Clinically, they may remain asymptomatic, but 
often manifest with epileptic seizures, gross hemorrhages, focal neurological deficits, and/or 
headache [7, 24, 26].  
Cavernous malformations may be sporadic or inherited in an autosomal dominant fashion 
with a high penetrance [9, 11]. While sporadic CCMs are often solitary, the familial form is 
usually associated with multiple lesions [26]. In genetic studies, three genetic loci have been 
defined [5]: CCM1 on chromosome 7q21-q22 (MIM 116860) accounting for 40% of all 
familial cases [6, 9, 11, 18], CCM2 on 7p13-p15 (MIM 603284) accounting for 13–20% [17, 
29], and CCM3 on 3q25.2-q27 (MIM 603285) for 40% [2].  
In this study, we present the clinical and genetic features of 19 Swiss families with inherited 
CCMs. 
 
Patients and methods 
The families were ascertained by a national search procedure performed at eight Swiss 
regional and university hospitals. Criteria for inclusion in this study were neuroradiologically 
diagnosed and/ or histopathologically proven CCMs of the CNS in at least two family 
members. By this search, 19 families of Swiss origin with inherited CCMs were obtained 
from five hospitals (Aarau, Basle, Berne, Lausanne, and Zurich). In the affected individuals, 
both clinical and genetic data were analyzed. If symptomatic parent–offspring pairs were 
available, we also measured anticipation by intergenerational comparison of mean age at 
symptom onset. Genetic analyses for CCM1 and CCM2 have been performed by the use of 
methods previously described [10, 17, 28, 29]. Due to logistic and financial reasons, we 
focussed on the index patients for genetic analysis. Type and outcome of surgical procedures 
were also presented. This study was approved by the Committee for the Protection of Human 
Subjects at the Dartmouth College, New Hampshire, USA.  
 
Results 
 
Demographic data 
The 19 families comprised a total of 56 affected individuals. In these families, between two 
and four generations were affected. Thirty-three (59%) individuals were females and 23 
males. The number of affected individuals per family ranged from 2 to 6.  
Clinicopathological features 
Of the 56 affected individuals, 12 (21%) were asymptomatic. These individuals have been 
identified in the scope of family screening. In the 44 symptomatic individuals, the most 
frequent manifestations encountered were epilepsy (16 or 36%), followed by focal 
neurological deficits (14 or 32%), hemorrhage (8 or 18%), and headache (6 or 14%). The 
mean age at symptom onset was 27.9 years (range, 1 to 79 years). Individuals with epilepsy 
became first symptomatic (mean age at onset 19.7 years), followed by headache (29.2 years), 
focal neurological deficits (29.3 years), and hemorrhages (40.6 years). Ten affected 
symptomatic individuals had an offspring with clinical symptoms. Of these parent–offspring 
pairs, the mean age at first clinical manifestation was 37.8 years in the first and 20.4 years in 
the second generation. Of the 56 affected individuals, 32 (57%) harbored multiple CCMs 
(range 2 to 78 lesions), whereas, 24 (43%) had a single lesion. Of the 19 index individuals, 12 
(63%) harbored multiple lesions and seven had single ones.  
Genetic features 
Of 37 individuals, genetic analysis has not been performed due to financial and logistic 
reasons. However, genetic analysis could be performed in 19 individuals representing all 19 
families. Of these, in nine individuals (47%), a mutation in CCM1 has been found. The 
observed CCM1 mutations comprised frameshifts in four individuals (44%), nonsense 
mutations in three (33%), changes in the invariant splice junctions and missense mutations in 
each one (11% each). Six individuals (32%) had a CCM2 mutation consisting of two 
frameshift and one nonsense mutation. In the remaining individuals, we did not screen for 
CCM3.  
Surgical treatment 
None of the 12 asymptomatic individuals have been operated for their CCMs. Of the 44 
symptomatic cases, 24 (55%) were surgically treated. Of these, 14 were operated on for their 
medically refractory epilepsy, five for a hemorrhage, and five for focal neurological deficits. 
The mean age at surgery was 29.4 years. All procedures performed included lesionectomy and 
in cases with epilepsy, additional resection of the surrounding hemosiderin rim. There was no 
perioperative mortality, and the perioperative morbidity was 4% (1/24). Two patients with 
epilepsy refused an operation. Of the 14 patients surgically treated for epilepsy, 11 (78%) 
became seizure-free postoperatively and only three had rare seizures (one to two seizures per 
year) following surgery. Of the 11 seizure-free patients, antiepileptic drugs could be tappered 
off in three patients.  
 
Discussion 
 
Familial CCMs of the central nervous system have first been described 80 years ago. In 1928, 
Hugo Friedrich Kufs reported on a family in which he assumed a common pathological basis 
in two members [15] (Fig. 1). He reported on an 81-year-old man in whom multiple cerebral 
and hepatic cavernomas have been found in an autopsy. His daughter presented with an 
“apoplexia pontis” with a right-sided hemiparesis and hemihypesthesia at the age of 17 years. 
Although CCMs have not been pathologically confirmed in the daughter, Kufs has to be given 
the credit for the first description of this entity. By the use of magnetic resonance imaging, 
further families have increasingly reported. Thus, since the first description, almost 1,000 
families have been reported all over the world [5, 16, 26]. Despite this large number of 
families reported, the prevalence of the inherited form of CCM is still not known yet. In early 
“semiepidemiological” studies in hispanics, a prevalence of inherited CCM of up to 50% has 
been suggested [22]. The high prevalence of CCMs in this ethnic group, however, is due to a 
“founder mutation” in the CCM1 gene that caused a sample bias [12, 13]. In later studies, this 
high prevalence could not be confirmed for other ethnic populations. Large epidemiologically 
based national studies in France and other studies have shown a lower but still undetermined 
prevalence for inherited CCMs [16, 27]. Here, we report 19 families found in Switzerland 
(with a population of 7.5 million) indicating a very low prevalence. However, our study 
comprises several methodological biases. Firstly, we did not perform screening by MRI in 
family members of individuals with CCMs as other studies have been previously performed 
[16]. Secondly, individuals who were not referred to one of the involved hospitals were not 
object to our study. Thirdly, we were not able to detect families with asymptomatic 
individuals only. Thus, to determine an accurate prevalence, further epidemiological studies 
have to be established.  
 
Clinicopathological features 
Clinically, inherited CCMs do not differ from the sporadic form. Both in sporadic and 
inherited CCMs 20% to 50% of patients with CCMs remain asymptomatic [3, 19, 26]. 
Between 41% and 59% of symptomatic cavernomas are associated with recurrent epileptic 
seizures, which are drug resistant in about 40% of cases [3, 4]. The estimated risk for seizure 
development was estimated at 1.51% per patient and year, or 2.48% per lesion and year in 
patients with multiple lesions [7]. CCMs may also cause major hemorrhages in 9% to 70% 
with a reported annual risk between 1% to 4%, while being associated with a higher risk of 
hemorrhage after an initial hemorrhagic event and in localizations involving deep structures 
or the brain stem [3, 23, 27].  
Other clinical manifestations are focal neurologic deficits and headache [7, 20, 21]. Similar 
clinical data have been reported for familial CCMs. In a literature review of 109 families with 
379 individuals with inherited CCMs, 91 (24%) were asymptomatic and 288 (76%) presented 
with symptoms comprising epileptic seizures (in 43%), followed by major hemorrhages (in 
28%), chronic headache (in 23%), or focal neurological deficits (in 15%) [26]. In our series, 
clinical features were in line with these previous studies.  
Here, we also analyzed the clinical data for the phenomenon of anticipation. The term 
“anticipation” refers to a progressively earlier age of symptom onset and/or increase in 
severity of an inherited disease in successive generations. In a previous study, we have shown 
that the mean age at first clinical manifestation decreased across generations from 32.7 years 
in the first generation to 18.0 years in the second generation then to 7.7 years in the third 
generation [26]. In this study, ten parent–offspring pairs could be analyzed for anticipation. 
These intergenerational pairs showed a decreased mean age at symptom onset in the offspring 
(20.4 years) compared to the parents (37.8 years). While expansion of unstable trinucleotide 
repeat has been found as the cause for anticipation in various neurological diseases, the cause 
for this phenomenon in CCMs is still not known [26].  
In our series, 57% of the affected individuals harbored multiple CCMs, and 43% had single 
malformations. This corresponds to previous studies reporting multiple lesions in up to 69% 
of familial cases [26]. These numbers support previous findings that carriers of multiple 
CCMs are more often associated with the familial form of this disease, but a solitary lesion 
does not exclude inheritance [26]. This awareness of this finding is important for genetic 
counseling.  
Genetic aspects and counseling 
Genetic analysis identified three CCM loci: CCM1 on chromosome 7q21-q22 accounting for 
40% of all familial cases, CCM2 on 7p13-p15 accounting for 13–20%, and CCM3 on 3q25.2-
q27 for up to 40% [5, 29].  
The gene CCM1 encodes for a 736 amino acids protein called the "Krev Interaction Trapped 
1" (Krit 1) protein. Krit1 contains three ankyrin repeats, a FERM (Band 4.1, ezrin, radixin, 
and moesin) domain and a NPXY (Asn-Pro-X-Tyr) motif. Molecular studies show that the 
NPXY motif seem to modulate a strong interaction with the integrin cytoplasmic domain-
associated protein 1 (icap1), suggesting that this protein might be involved in bidirectional 
signaling between the integrin and the cytoskeleton in CCM1 pathogenesis [31]. In addition, 
Krit1 has been shown to be a microtubule-associated protein that may help determine 
endothelial cell shape and function in response to cell–cell and cell–matrix interactions by 
guiding cytoskeletal structure [14]. The CCM2 gene found at locus 7p13-p15 encodes for the 
“Malcavernin” protein [8, 17]. “Malcavernin” is a similar protein as the Krit 1 binding partner 
ICAP1, a protein with a phosphotyrosin binding domain [32]. Recently, the PDCD10 
(Programmed Cell Death 10) gene also called TFAR15 has been identified as the CCM3 gene 
[2]. Although the product and function of PDCD10 is still not known, it is thought to interact 
with angiogenesis.  
In our series, genetic analysis could be performed in 19 individuals. The mutations found 
were mainly in the CCM1 gene (in nine individuals) and less commonly in CCM2 (in six 
individuals). Type of mutations were reported in detail elsewhere [10, 28, 30]. In four 
individuals, neither in CCM1 nor in CCM2 mutations have been found indicating a mutation 
in CCM3. Recently, some studies have suggested that an additional gene (CCM4) might be 
involved since there were some affected in whom no mutations could be detected in the three 
known CCM genes.  
Surgical outcome 
Since CCMs are often symptomatic, a surgical treatment becomes mandatory. There is a large 
variety of studies reporting excellent surgical outcome following removal of CCMs [1, 3, 7, 
21]. Thus, in a large series of 72 patients, there was no mortality, and the immediate 
perioperative morbidity rate was 29.2% (21/72), while the rate of long-term morbidity was 
5.5% (4/72). Similarly, in our series of familial CCMs, there was also no mortality, and the 
long-term morbidity was 4%. Surgery has particularly proven to be an effective treatment in 
CCMs manifesting with epilepsy. Patients become seizure-free in about 70% to 80% [1, 3]. In 
our patients, 11 of 14 (78%) became seizure-free. This excellent result gets endorsed by the 
fact that antiepileptic drugs could be tapered off after surgery in three patients. None of our 
patients have been operated on for multiple CCMs. Analogously to sporadic cases in patients 
with multiple CCMs, the question is under debate whether more than the symptomatic 
malformation should be removed. So far, there are no guidelines, and often, the 
neurosurgeon’s philosophy is decisive. Another important issue is the management of 
asymptomatic affected individuals. Here, the annual risk of hemorrhages or seizures has to be 
weighed in contrast to the risk of an operation. Though, there are no strict guidelines in either 
of these cases, the indication for surgery should be given rather cautiously.  
 
Conclusion 
Although accurate prevalence data are still not available, the familial occurrence of CCMs 
seems to be underestimated. Therefore, each individual with CCMs has to be thoroughly 
interviewed for a positive family history. However, the identification of other affected family 
members might be facilitated in the future by the use of increasingly available genetic testing. 
Current genetic studies focuses on the search for additional genes causing CCMs. While 
CCMs may remain asymptomatic, they are often symptomatic and an operation may become 
mandatory.  
In the management of this entity, some questions still have to be answered. Thus, it is still 
debatable whether asymptomatic individuals with familial CCMs should also be surgically 
treated. Furthermore, the methodological drawbacks of our study mentioned above might be 
reduced by establishing a center for this disorder in Switzerland.  
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